HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Respiratory depression caused by opioid — Clinical Guidelines

Overview

Respiratory depression caused by opioids is characterized by a significant decrease in respiratory rate and depth, potentially leading to hypoxia and life-threatening complications. It often occurs as a side effect of opioid administration and can be exacerbated by certain patient characteristics and concurrent medications. 2 4

Diagnosis

Clinical Signs: Decreased respiratory rate, altered mental status, hypoxia (low oxygen saturation).

Monitoring: Continuous pulse oximetry, capnography, and respiratory rate monitoring.

Risk Factors: Female sex, comorbid renal disease, untreated sleep apnea, use of long-acting oxycodone, and as-needed hydromorphone use. 2

Management

First-Line Treatments:

- Naloxone: For immediate reversal of opioid-induced respiratory depression (dose varies based on severity).

Adjunctive Treatments:

- 5-HT1A Receptor Agonists: Befiradol (0.2 mg/kg) can reduce respiratory depression without compromising analgesia or sedation. 4 - Non-Opioid Analgesics: Consider alternatives like lidocaine for perioperative analgesia to avoid opioid use. 1

Special Populations

Comorbidities: Patients with renal disease and untreated sleep apnea are at higher risk for oversedation and respiratory depression. 2

Route of Administration: Oral or intravenous administration of as-needed analgesia shows protective effects against oversedation. 2

Key Recommendations

Monitor high-risk patients (female sex, renal disease, untreated sleep apnea) closely for signs of oversedation and respiratory depression. (Evidence: Moderate) 2

Utilize naloxone for the reversal of opioid-induced respiratory depression, adjusting dose according to clinical response. (Evidence: Expert opinion)

Consider non-opioid analgesics like lidocaine for perioperative pain management to minimize opioid exposure. (Evidence: Strong) 1

Explore the use of 5-HT1A receptor agonists such as befiradol to mitigate respiratory depression without affecting analgesia or sedation in appropriate clinical settings. (Evidence: Moderate) 4

References

1 Cha NH, Hu Y, Zhu GH, Long X, Jiang JJ, Gong Y. Opioid-free anesthesia with lidocaine for improved postoperative recovery in hysteroscopy: a randomized controlled trial. BMC anesthesiology 2023. link 2 Brant JM, Stringer L, Jurkovich LR, Coombs NC, Mullette EJ, Buffington C et al.. Predictors of oversedation in hospitalized patients. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2018. link 3 Borges LP, Nishimura LT, Carvalho LL, Cerejo SA, Auckburally A, Mattos-Junior E. Behavioral and cardiopulmonary effects of dexmedetomidine alone and in combination with butorphanol, methadone, morphine or tramadol in conscious sheep. Veterinary anaesthesia and analgesia 2016. link 4 Ren J, Ding X, Greer JJ. 5-HT1A receptor agonist Befiradol reduces fentanyl-induced respiratory depression, analgesia, and sedation in rats. Anesthesiology 2015. link

Respiratory depression caused by opioid